It is believed that the transition from the hidden ...

On the other hand, the chances of ever a man with a diagnosis of clinical prostate cancer is less than 18%. It is believed that the transition from latent to clinical cancer requires the involvement and contribution of additional risk factors after the initial launch (Klein et al., 2007). A class of risk of prostate cancer is carried out in the genomes of some men. The tendency to the development of prostate cancer can be inherited, but men are more likely to get prostate cancer if the relatives have the disease. Evidence that this effect is genetic, not environmental comes from the observation that monozygotic twins show more effect than dizygotic twins (Grönberg, 2003). Some families are suffering from a particularly "strong" genes for prostate cancer addiction. In these families, not only have a greater tendency than usual for men to get prostate cancer levaquin side effects last, the disease also strikes at younger ages (55 years). To date, more than 8 "strong" genes for prostate cancer susceptibility have been identified and their mechanisms of action are currently being worked out (Gretzer Partin, 2007). About 15% of cases of prostate cancer genes are determined by the strengths of prostate. This so-called

a family or hereditary prostate cancer. The remaining 85% of cases of prostate cancer is called

sporadic, because they occur in patients whose families do not show clustering of cancer cases in which prostate cancer usually develops later in men aged 70 and older. Many external influences have been linked to prostate cancer.